With Trio Of 2011 Deals, Alexion Looks To Nearly Double R&D Spending In 2012

The biotech, which is enjoying growing sales of high-priced, ultra-orphan terminal complement inhibitor Soliris, also has a pipeline of four other clinical and preclinical candidates for rare diseases.